Grufity logoGrufity logo

ATRC

45.96USD+0.40(+0.88%)Market Closed

AtriCure Inc

Market Summary

USD45.96+0.40Market Closed
0.88%

ATRC Alerts

ATRC Stock Price

RSI Chart

Valuation

Market Cap

1.9B

Price/Earnings

36.47

Price/Sales

6.43

Price/Cashflow

-95.68

MarketCap/EBT

36.34

Price/Sales

Profitability

Operating Margin

74.76%

EBT Margin

17.68%

Return on Equity

11.68%

Return on Assets

9.08%

Fundamentals

Revenue

Revenue (TTM)

315.6M

Revenue Y/Y

18.15%

Revenue Q/Q

-1.52%

Earnings

Earnings (TTM)

-56.0M

Earnings Y/Y

-112.64%

Earnings Q/Q

17.31%

Price Action

52 Week Range

32.5174.85
(Low)(High)

Last 7 days

1.3%

Last 30 days

7.0%

Last 90 days

7.3%

Trailing 12 Months

-29.9%

Financial Health

Current Ratio

3.66

Investor Care

Shares Dilution (1Y)

1.26%

Diluted EPS (TTM)

-1.22

Peers (Alternatives to AtriCure)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
10.2T
429.9M
-13.56% 48.60%
185.5K
28.0K
144.70% 331.94%
86.7B
17.9B
9.40% 1.57%
41.71
4.92
7.67% 29.32%
86.3B
6.1B
11.19% -14.20%
62.6
14.1
11.47% -18.42%
67.1B
18.9B
7.25% 7.47%
38.21
3.25
-6.81% -14.96%
61.8B
12.3B
7.86% 20.92%
69.9
5.01
10.11% 51.89%
43.9B
5.4B
6.85% -27.80%
30.09
8.18
5.29% -1.25%
MID-CAP
6.7B
998.4M
12.82% 19.67%
44.21
6.87
6.04% -19.01%
6.4B
806.4M
29.82% -13.72%
-331.15
7.96
20.10% -221.96%
3.9B
380.1M
-14.51% 1.73%
-29.57
10.69
18.85% -63.58%
3.6B
790.7M
-23.89% -65.81%
-273.58
4.7
19.65% -412.22%
SMALL-CAP
1.6B
126.8M
20.67% 27.67%
-26.38
14.01
34.44% -10.05%
1.1B
291.9M
5.19% 0.37%
-6.57
3.67
52.45% -57.74%
1.0B
795.9M
20.86% -8.66%
-131.34
1.33
8.11% 182.50%
606.7M
236.2M
-3.52% -27.68%
-16.43
2.57
-8.79% -175.19%

Financials for AtriCure

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue4.2%316303290274259
Cost Of Revenue4.3%8076736866
Gross Profit4.2%236226217206193
Operating Expenses70.8%287168160151143
  S&GA Expenses3.3%229222217205201
  R&D Expenses7.3%5754514946
Earnings Before Taxes-204.3%-55.8454525046
Net Income-205.1%-56.0453525045
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-0.9%582587585615613
  Current Assets3.0%212206200196196
    Cash Equivalents-10.5%4955284440
  Inventory6.4%4441413939
  Net PPE6.9%3936333130
  Goodwill0%235235235235235
Liabilities0.7%132131122132125
  Current Liabilities2.3%5856475654
    LT Debt, Non Current0.2%6060606056
Shareholder's Equity-1.4%450457463484488
  Retained Earnings-4.0%-322.45-310.18-295.34-280.15-266.41
  Additional Paid-In Capital0.9%778771762765755
Shares Outstanding0.0%4646464646
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-7.6%-21.89-20.33-29.10-13.78-10.13
  Share Based Compensation0.7%2929292827
Cashflow From Investing134.8%3816-20.362420
Cashflow From Financing22.1%-6.53-8.39-7.43-7.64-3.70

Risks

What is the probability of a big loss on ATRC?

90%


Probability that AtriCure stock will be more than 20% underwater in next one year

54.2%


Probability that AtriCure stock will be more than 30% underwater in next one year.

30%


Probability that AtriCure stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ATRC drawdown profile look like?

Y-axis is the maximum loss one would have experienced if AtriCure was unfortunately bought at previous high price.

Returns

Cumulative Returns on ATRC

21.6%


10-Year Cumulative Returns

11.5%


7-Year Cumulative Returns

19.9%


5-Year Cumulative Returns

15.8%


3-Year Cumulative Returns

What are the long-term rolling returns for ATRC?

FIve years rolling returns for AtriCure.

Which funds bought or sold ATRC recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-2.27
-152,000
2,183,000
-%
2022-11-17
CENTRAL TRUST Co
REDUCED
-4.5
-1,000
12,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
REDUCED
-16.48
-55,000
218,000
-%
2022-11-16
Advisors Capital Management, LLC
ADDED
21.88
569,000
2,091,000
0.06%
2022-11-15
Truvestments Capital LLC
UNCHANGED
-
-
5,000
-%
2022-11-15
ALGERT GLOBAL LLC
ADDED
515.59
1,281,000
1,543,000
0.09%
2022-11-15
CASTLEARK MANAGEMENT LLC
SOLD OFF
-100
-3,591,000
-
-%
2022-11-15
Neuberger Berman Group LLC
ADDED
6.32
379,000
21,226,000
0.02%
2022-11-15
MAI Capital Management
REDUCED
-0.01
-24,000
531,000
0.01%
2022-11-15
STATE STREET CORP
ADDED
0.29
-1,725,000
41,101,000
-%

1–10 of 48

Latest Funds Activity

Are funds buying ATRC calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own ATRC

AtriCure News

Best Stocks

Brokerages have assigned a consensus rating of "Moderate Buy" to AtriCure, Inc. (NASDAQ:ATRC)..4 days ago

Thehour.com

ATRC Fair Value

Recent SEC filings of AtriCure

View All Filings
Date Filed Form Type Document
Nov 21, 2022
4
Insider Trading
Nov 02, 2022
10-Q
Quarterly Report
Nov 01, 2022
8-K
Current Report
Sep 19, 2022
4
Insider Trading
Sep 02, 2022
4
Insider Trading

Latest Insider Trading transactions for ATRC

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-17
CARREL MICHAEL H
GIFTED
-
-
-6,000
President, CEO, & Director
2022-09-15
Doraiswamy Vinayak
SOLD
-229,168
45.99
-4,983
Chief Scientific Officer
2022-08-31
WHITE ROBERT S.
ACQUIRED
127,200
8.48
15,000
-
2022-08-06
Wirick Angela L
SOLD (Taxes)
-264,430
50.94
-5,191
Chief Financial Officer
2022-06-30
Dahlquist Karl S.
ACQUIRED
12,155.5
34.73
350
Chief Legal Officer
2022-06-30
Doraiswamy Vinayak
ACQUIRED
12,155.5
34.73
350
Chief Scientific Officer
2022-06-30
CARREL MICHAEL H
ACQUIRED
12,155.5
34.73
350
President, CEO, & Director
2022-06-30
Privitera Salvatore
ACQUIRED
12,155.5
34.73
350
Chief Technical Officer
2022-06-01
Yount Deborah Lee
ACQUIRED
-
-
16,900
Chief Human Resources Officer
2022-05-25
WHITE ROBERT S.
ACQUIRED
-
-
3,564
-

1–10 of 50

Michael H. Carrel
880
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

ATRC Income Statement

2022-09-30
Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Revenue$ 83,246$ 70,460$ 242,351$ 201,111
Cost of revenue21,53318,23461,52450,267
Gross profit61,71352,226180,827150,844
Operating expenses (benefit):    
Research and development expenses15,16911,28443,58934,698
Selling, general and administrative expenses57,26749,873175,771150,939
Change in fair value of contingent consideration0(189,900)0(184,800)
Intangible asset impairment082,300082,300
Total operating expenses (benefit)72,436(46,443)219,36083,137
(Loss) income from operations(10,723)98,669(38,533)67,707
Other income (expense):    
Interest expense(1,324)(1,449)(3,425)(3,835)
Interest income370117562354
Other(549)(191)(753)(151)
(Loss) income before income tax expense(12,226)97,146(42,149)64,075
Income tax expense4638147135
Net (loss) income$ (12,272)$ 97,108$ (42,296)$ 63,940
Net (loss) income per share    
Basic net income (loss) per share (in usd per share)$ (0.27)$ 2.15$ (0.93)$ 1.42
Diluted net income (loss) per common share (in usd per share)$ (0.27)$ 2.11$ (0.93)$ 1.39
Weighted average shares outstanding    
Weighted average shares outstanding—basic (in shares)45,82345,25845,68244,977
Weighted average shares outstanding—diluted (in shares)45,82346,10045,68245,996
Comprehensive (loss) income:    
Unrealized loss on investments$ (691)$ (14)$ (3,479)$ (177)
Foreign currency translation adjustment(260)(112)(868)(348)
Other comprehensive loss(951)(126)(4,347)(525)
Net (loss) income(12,272)97,108(42,296)63,940
Comprehensive (loss) income, net of tax$ (13,223)$ 96,982$ (46,643)$ 63,415

ATRC Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 48,823$ 43,654
Short-term investments73,82175,436
Accounts receivable, less allowance for credit losses of $1,09641,46633,021
Inventories43,95338,964
Prepaid and other current assets4,2225,001
Total current assets212,285196,076
Long-term investments51,413104,338
Property and equipment, net38,55631,409
Operating lease right-of-use assets3,9694,761
Intangible assets, net40,07842,992
Goodwill234,781234,781
Other noncurrent assets829955
Total Assets581,911615,312
Current liabilities:  
Accounts payable24,40518,597
Accrued liabilities31,16236,092
Current maturities of leases2,0311,756
Total current liabilities57,59856,445
Long-term debt60,06159,741
Finance lease liabilities9,40710,082
Operating lease liabilities3,3144,068
Other noncurrent liabilities1,2231,220
Total Liabilities131,603131,556
Commitments and contingencies (Note 8)
Stockholders’ Equity:  
Common stock, $0.001 par value, 90,000 shares authorized and 46,443 and 46,016 issued and outstanding4646
Additional paid-in capital778,006764,811
Accumulated other comprehensive loss(5,295)(948)
Accumulated deficit(322,449)(280,153)
Total Stockholders’ Equity450,308483,756
Total Liabilities and Stockholders’ Equity$ 581,911$ 615,312